Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

The liver fibrosis market is entering a transformative phase, driven by greater awareness, improved diagnostic ...

The HARMONY study compared two doses of Akero's FGF21 mimic efruxifermin to placebo over 24 weeks in 128 adult patients with biopsy-confirmed NASH, a serious form of non-alcoholic fatty liver ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general population and is ...

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis ... (F4) due to NASH, a form of non-alcoholic fatty liver disease ...

EFX, Akero’s lead product candidate for MASH, is currently being evaluated in three ongoing Phase 3 studies. In multiple Phase 2 studies, EFX has been observed to reverse fibrosis, resolve MASH, ...

SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

This is what keeps your liver in working order, plus how alcohol, viruses, unhealthy foods and some supplements get in the way. Use these tips to keep it healthy.

A high-level overview of Akero Therapeutics, Inc. (AKRO) stock. View (AKRO) real-time stock price, chart, news, ... Akero raised to Buy at Bank of America after liver drug data SA News Thu, Jan. 30.